Christopher Perley has been named vice president and general manager of Bristol-Myers Squibb’s Devens biologics manufacturing facility. Mr. Perley will be responsible for continuing the supervision of the project to build the Devens facility and will have overall management responsibility for the site when it becomes operational in 2011.
    
“With an approved capital expenditure of $750 million, the Devens facility represents the largest capital investment in the history of Bristol-Myers Squibb,” said Carlo de Notaristefani, president of technical operations, BMS. “As the company evolves toward a next-generation biopharma model, combining the best of biotech with the best of a traditional pharmaceutical company, biologics will play an increasingly important role in driving our company’s future growth and success, and will be key in helping patients prevail over serious disease. Chris brings extensive biopharmaceutical experience that will support the company in this transition.”
   
Prior to joining the company, Mr. Perley was vice president of network strategy at Wyeth Biotech, where he gained experience in biopharmaceutical process development, production, supply chain management, and operations. Previously, he held manufacturing and biotechnology process development roles at the Genetics Institute in Andover, MA, and at Hoffmann-La Roche in Nutley, NJ.